Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-pa

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has advanced with the publication in the United States of a patent application

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has advanced with the publication in the United States of a patent application

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem – a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape.  Ground

Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases. GM2 gangliosidosis is a rare, inherited disorder that progressively destroys nerve cells in the brain and spinal cord. While the most common form presents in infancy,

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody intermediates and drug substances of bioconjugates at Singapore site has successfully achieved GMP release. This milestone marks a new phase in the company's global capacity expansion, empowering clients worldwide to accelerate c

Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech company focused on creating best-in-class PROTACs (proteolysis targeting chimera) and DACs (degrader antibody conjugates) therapeutics, today announced the initiation of a Phase I clinical trial evaluating PHT-776/HPB-143, an investigational IRAK4 PROTAC candidate. PHT-776/HPB-143 is an oral IRAK4-targeted PROTAC des

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). This marks the

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, today announced the signing of a Memorandum of Understanding (MoU) with Alfresa Holdings Corporation, one of Japan’s leading healthcare and pharmaceutical distribution groups, to establish a strategic collaboration for the development and future distribution of its lead product candidate ProtheraCytes® in Japan. The agreement follows the recent publication of the EXCELLENT clinical trial

University of Queensland researchers will accelerate life-changing health research after securing $29 million from the National Health and Medical Research Council (NHMRC).  The funding will support researchers at all career stages to establish innovative programs tackling major health challenges, including cancer, chronic disease, chronic pain, schizophrenia and fetal alcohol spectrum disorder (FASD).   The NHMRC Investigator Grants scheme allows recipients to f